Rafael Bejar, MD, PhD, head of the MDS Center of Excellence at the University of California, San Diego, explains how the small number of
mutation-driven MDS treatments remains a challenge. These treatments include
targeted therapy for mutations in the genes
IDH1 and
IDH2, as well as luspatercept for people with a mutation in
SF3B1. Learning about
resistance mutations is also important for improving treatment response and developing additional mutation-driven MDS therapies.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.